Daclizumab (Subcutaneous)
Medically reviewed by Drugs.com. Last updated on Mar 23, 2022.
Hepatic Injury Including Autoimmune HepatitisDaclizumab can cause severe liver injury, including autoimmune hepatitis and liver failure. Fatal cases have occurred. Obtain transaminase and bilirubin levels before initiation of daclizumab. Monitor and evaluate transaminase and bilirubin levels monthly and up to 6 months after the last dose.Daclizumab is contraindicated in patients with pre-existing hepatic disease or hepatic impairment.Other Immune-Mediated DisordersImmune-mediated disorders including skin reactions, lymphadenopathy, non-infectious colitis, and other immune-mediated disorders can occur with daclizumab.These conditions may require treatment with systemic corticosteroids or immunosuppressive medication.Daclizumab is available only through a restricted distribution program called the ZINBRYTA(R) REMS Program .
Commonly used brand name(s)
In the U.S.
- Zinbryta
Pharmacologic Class: Monoclonal Antibody
Uses for daclizumab
Daclizumab injection is used to treat the relapsing forms of multiple sclerosis (MS). Daclizumab will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used when other medicines to treat MS did not work well.
Daclizumab was available only under a restricted distribution program called the Zinbryta® REMS (Risk Evaluation and Mitigation Strategy) Program.
Daclizumab was voluntarily withdrawn from the worldwide market on March 2, 2018 due to safety concerns.
Before using daclizumab
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For daclizumab, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to daclizumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of daclizumab injection in children younger than 17 years of age. Use of daclizumab injection in children is not recommended because of the risk for liver damage and immune system disorders. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of daclizumab injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking daclizumab, it is especially important that your healthcare profession..
